nach oben

Neurological Sciences

Erschienen in:

15.02.2022 | Original Article

Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease

verfasst von: Fardin Nabizadeh, Kasra Pirahesh, Elham Khalili

Erschienen in: Neurological Sciences | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The prevalence of olfactory impairment in patients with Parkinson’s disease (PD) is 50–90%, and therefore, olfactory dysfunction is one of the most prevalent non-motor symptoms (NMSs) in patients with PD. Numerous studies have evaluated the association between motor and non-motor symptoms and olfactory dysfunction in PD.

Aim

In this study, we investigated the relationship between olfactory dysfunction, which is measured using the UPSIT test, with other motor and non-motor symptoms separately in three motor subtypes of PD, including tremor dominant (TD), postural instability and gait difficulty (PIGD), and indeterminate and healthy subjects.

Methods

We recruited 487 early-stage PD patients (43 PIGD, 406 TD, and 38 indeterminate) and healthy controls (HCs) (n = 197) from the Parkinson Progression Markers Initiative (PPMI). All participants completed motor and non-motor tests at baseline visit and after 4 years of follow-up. Subjects underwent common PD scaling tests.

Results

Olfactory dysfunction was significantly correlated with declined motor functions only in the TD subtype. Also, significant correlations were noticed between olfactory dysfunction and speed-attention processing and executive function in the HCs as well. Finally, no significant or meaningful association was observed in the PIGD and indeterminate subtype. Anosmia and hyposmia subjects in the TD group had the worse motor and non-motor scores compared to normosmia subjects after 4 years.

Conclusion

Olfactory dysfunction was significantly correlated with declined motor functions in the TD subtype. This is indicating that olfactory dysfunction may be an early motor and non-motor biomarker only in the TD subtype. However, it is possible that the involvement of olfactory function in other subtypes is not strong enough to make it a useful marker of diseases progression.

Trentin S, Fraiman de Oliveira BS, Ferreira Felloni Borges Y, de Mello Rieder CR (2021) Systematic review and meta-analysis of Sniffin Sticks Test performance in Parkinson's disease patients in different countries. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-021-06970-8

Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8(s1):S3–S8. https://doi.org/10.3233/JPD-181474CrossRefPubMedPubMedCentral

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE (2017) Parkinson disease. Nature Reviews Disease Primers 2017 3:1 3 (1):1–21 https://doi.org/10.1038/nrdp.2017.13

Eek T, Larsson M, Dizdar N (2021) Odor Recognition memory in Parkinson’s disease: a systematic review. Frontiers in Aging Neuroscience 13:625171–625171. https://doi.org/10.3389/FNAGI.2021.625171CrossRefPubMedPubMedCentral

Fullard ME, Morley JF, Duda JE (2017) Olfactory dysfunction as an early biomarker in Parkinson’s disease. Neurosci Bull 33(5):515–515. https://doi.org/10.1007/S12264-017-0170-XCrossRefPubMedPubMedCentral

Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA, Kraneveld AD (2017) Exploring Braak’s hypothesis of Parkinson’s disease. Front in Neurol 8:1–1. https://doi.org/10.3389/FNEUR.2017.00037CrossRef

Morley JF, Cohen A, Silveira-Moriyama L, Lees AJ, Williams DR, Katzenschlager R, Hawkes C, Shtraks JP, Weintraub D, Doty RL, Duda JE (2018) Optimizing olfactory testing for the diagnosis of Parkinson’s disease: item analysis of the university of Pennsylvania smell identification test. npj Parkinson's Disease 2018 4:1 4 (1):1–7 https://doi.org/10.1038/s41531-017-0039-8

Wang J, You H, Liu JF, Ni DF, Zhang ZX, Guan J (2011) Association of olfactory bulb volume and olfactory sulcus depth with olfactory function in patients with Parkinson disease. Am J Neuroradiol 32(4):677–681. https://doi.org/10.3174/AJNR.A2350CrossRefPubMedPubMedCentral

Yoo HS, Chung SJ, Lee YH, Ye BS, Sohn YH, Lee PH (2020) Association between olfactory deficit and motor and cognitive function in parkinsons disease. J of Mov Disord 13(2):133–141. https://doi.org/10.14802/JMD.19082CrossRef

10.

Rossi M, Escobar AM, Bril A, Vernetti PM, Palo JI, Cerquetti D, Merello M (2016) Motor features in Parkinson’s disease with normal olfactory function Movement disorders. off j of the Mov Disord Soc 31(9):1414–1417CrossRef

11.

Qian E, Huang Y (2019) Subtyping of Parkinson’s disease - where are we up to. Aging Dis 10(5):1130–1139. https://doi.org/10.14336/AD.2019.0112CrossRefPubMedPubMedCentral

12.

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W, Group PS (1990) Variable expression of Parkinsons disease. Neurol 40(10):1529–1529. https://doi.org/10.1212/WNL.40.10.1529CrossRef

13.

Huang X, Ng SYE, Chia NSY, Setiawan F, Tay KY, Au WL, Tan EK, Tan LCS (2019) Non-motor symptoms in early Parkinson’s disease with different motor subtypes and their associations with quality of life. Eur J Neurol 26(3):400–406. https://doi.org/10.1111/ENE.13803CrossRefPubMed

14.

Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50(6):743–755. https://doi.org/10.1097/00005072-199111000-00006CrossRefPubMed

15.

Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B (2005) Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord 20(9):1133–1142. https://doi.org/10.1002/MDS.20513CrossRefPubMedPubMedCentral

16.

Herman T, Weiss A, Brozgol M, Giladi N, Hausdorff JM (2014) Gait and balance in Parkinson’s disease subtypes: objective measures and classification considerations. Journal of Neurology 2014 261:12 261 (12):2401–2410. https://doi.org/10.1007/S00415-014-7513-6

17.

Herman T, Weiss A, Brozgol M, Wilf-Yarkoni A, Giladi N, Hausdorff JM (2014) Cognitive function and other non-motor features in non-demented Parkinson’s disease motor subtypes. Journal of Neural Transmission 2014 122:8 122 (8):1115–1124 https://doi.org/10.1007/S00702-014-1349-1

18.

Xu C, Zhuang P, Hallett M, Zhang Y, Li J, Li Y (2018) Parkinson's Disease Motor Subtypes Show Different Responses to Long-Term Subthalamic Nucleus Stimulation. Front Hum Neurosci 12:365. https://doi.org/10.3389/fnhum.2018.00365

19.

Rezvanian S, Lockhart T, Frames C, Soangra R, Lieberman A (2018) Motor subtypes of Parkinson's disease can be identified by frequency component of postural stability. Sensors (Basel) 18(4):1102. https://doi.org/10.3390/s18041102

20.

Rudzińska M, Marona M, Bukowczan S, Banaszkiewicz K, Mirek E, Szczudlik A (2007) Falls in different types of Parkinson’s disease. Neurol Neurochir Pol 41(5):395–403PubMed

21.

Choi S-M, Kim BC, Cho B-H, Kang KW, Choi K-H, Kim J-T, Lee S-H, Park M-S, Kim M-K, Cho K-H (2018) Comparison of two motor subtype classifications in de novo Parkinson’s disease. Parkinsonism Relat Disord 54:74–78. https://doi.org/10.1016/J.PARKRELDIS.2018.04.021CrossRefPubMed

22.

Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov disord off j of the Mov Disord Soc 28(5):668–670. https://doi.org/10.1002/mds.25383CrossRef

23.

Masala C, Solla P, Liscia A, Defazio G, Saba L, Cannas A, Cavazzana A, Hummel T, Haehner A (2018) Correlation among olfactory function, motors’ symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson’s disease. J Neurol 265(8):1764–1771. https://doi.org/10.1007/s00415-018-8913-9CrossRefPubMed

24.

He R, Zhao Y, He Y, Zhou Y, Yang J, Zhou X, Zhu L, Zhou X, Liu Z, Xu Q, Sun Q, Tan J, Yan X, Tang B, Guo J (2020) Olfactory dysfunction predicts disease progression in Parkinson’s disease: a longitudinal study. Front Neurosci 14:569777. https://doi.org/10.3389/fnins.2020.569777CrossRefPubMedPubMedCentral

25.

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211. https://doi.org/10.1016/s0197-4580(02)00065-9CrossRefPubMed

26.

Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P (2018) (11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson’s: a longitudinal study. Mov Disord 33(1):117–127. https://doi.org/10.1002/mds.27183CrossRefPubMed

27.

Roos DS, Twisk JWR, Raijmakers P, Doty RL, Berendse HW (2019) Hyposmia as a marker of (non-)motor disease severity in Parkinson’s disease. J Neural Transm (Vienna) 126(11):1471–1478. https://doi.org/10.1007/s00702-019-02074-0CrossRef

28.

Elhassanien MEM, Bahnasy WS, El-Heneedy YAE, Kishk AM, Tomoum MO, Ramadan KM, Allah Ragab OA (2021) Olfactory dysfunction in essential tremor versus tremor dominant Parkinson disease. Clin Neurol Neurosurg 200:106352. https://doi.org/10.1016/j.clineuro.2020.106352CrossRefPubMed

29.

Ondo WG, Lai D (2005) Olfaction testing in patients with tremor-dominant Parkinson’s disease: is this a distinct condition? Mov Disord 20(4):471–475. https://doi.org/10.1002/mds.20365CrossRefPubMed

30.

Kang P, Kloke J, Jain S (2012) Olfactory dysfunction and parasympathetic dysautonomia in Parkinson’s disease. Clin Auton Res 22(4):161–166. https://doi.org/10.1007/s10286-012-0158-6CrossRefPubMedPubMedCentral

31.

Zhao Y, He Y, He R, Zhou Y, Pan H, Zhou X, Zhu L, Zhou X, Liu Z, Xu Q, Sun Q, Tan J, Yan X, Tang B, Guo J (2020) The discriminative power of different olfactory domains in Parkinson’s disease. Front Neurol 11:420–420. https://doi.org/10.3389/fneur.2020.00420CrossRefPubMedPubMedCentral

32.

Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. The Lancet Neurol 7(7):583–590. https://doi.org/10.1016/s1474-4422(08)70117-0CrossRefPubMed

33.

Ferreira JJ, Guedes LC, Rosa MM, Coelho M, van Doeselaar M, Schweiger D, Di Fonzo A, Oostra BA, Sampaio C, Bonifati V (2007) High prevalence of LRRK2 mutations in familial and sporadic Parkinson’s disease in Portugal. Mov Disord 22(8):1194–1201. https://doi.org/10.1002/mds.21525CrossRefPubMed

34.

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH (2008) The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson’s disease: the GenePD study. BMC Med 6:32. https://doi.org/10.1186/1741-7015-6-32CrossRefPubMedPubMedCentral

35.

Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain : a j of neurol 128(Pt 12):2786–2796. https://doi.org/10.1093/brain/awh667CrossRef

36.

Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65(10):1353–1357. https://doi.org/10.1001/archneur.65.10.1353CrossRefPubMedPubMedCentral

37.

Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S, Tagliati M, Condefer K, Palmese C, Brüggemann N, Klein C, Roe A, Kornreich R, Ozelius L, Bressman S (2010) Gaucher disease ascertained through a Parkinson’s center: imaging and clinical characterization. Mov Disord 25(10):1364–1372. https://doi.org/10.1002/mds.23046CrossRefPubMedPubMedCentral

38.

Saunders-Pullman R, Stanley K, Wang C, San Luciano M, Shanker V, Hunt A, Severt L, Raymond D, Ozelius LJ, Lipton RB, Bressman SB (2011) Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurol 77(4):319–324. https://doi.org/10.1212/WNL.0b013e318227041cCrossRef

39.

von Coelln R, Shulman LM (2016) Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Curr Opin Neurol 29(6):727–734. https://doi.org/10.1097/wco.0000000000000384CrossRef

40.

Lee DH, Oh JS, Ham JH, Lee JJ, Lee I, Lee PH, Kim JS, Sohn YH (2015) Is normosmic Parkinson disease a unique clinical phenotype? Neurol 85(15):1270–1275. https://doi.org/10.1212/wnl.0000000000001999CrossRef

41.

Rossi M, Escobar AM, Bril A, Millar Vernetti P, De Palo JI, Cerquetti D, Merello M (2016) Motor features in Parkinson’s disease with normal olfactory function. Mov Disord 31(9):1414–1417. https://doi.org/10.1002/mds.26687CrossRefPubMed

42.

Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF (2016) Olfactory impairment predicts cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 25:45–51. https://doi.org/10.1016/j.parkreldis.2016.02.013CrossRefPubMedPubMedCentral

43.

Soudry Y, Lemogne C, Malinvaud D, Consoli SM, Bonfils P (2011) Olfactory system and emotion: common substrates. Eur Ann Otorhinolaryngol Head Neck Dis 128(1):18–23. https://doi.org/10.1016/j.anorl.2010.09.007CrossRefPubMed

44.

Hong JY, Sunwoo MK, Ham JH, Lee JJ, Lee PH, Sohn YH (2015) Apathy and olfactory dysfunction in early Parkinson’s disease. J Mov Disord 8(1):21–25. https://doi.org/10.14802/jmd.14029CrossRefPubMedPubMedCentral

45.

Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE (2011) Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson’s disease. Mov Disord 26(11):2051–2057. https://doi.org/10.1002/mds.23792CrossRefPubMedPubMedCentral

Titel: Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease
verfasst von: Fardin Nabizadeh
Kasra Pirahesh
Elham Khalili
Publikationsdatum: 15.02.2022
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 7/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-05952-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2022

Ultrasonographic evaluation reveals thinning of cervical nerve roots and peripheral nerves in spinal and bulbar muscular atrophy

Superficial siderosis in long-standing pilocytic astrocytoma

Anxiety and depression in Alzheimer’s disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline

A splice altering variant in NDRG1 gene causes Charcot-Marie-Tooth disease, type 4D

Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem)